Article
Treatment patterns and immunological parameters from the SPOCS study in Germany
Search Medline for
Authors
-
Martin Aringer
- University Medical Center, Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden
-
Julius Brandenburg
- Medical Affairs, AstraZeneca, Hamburg
-
Christian Körner
- Medical Affairs, AstraZeneca, Hamburg
-
Bo Ding
- BioPharmaceuticals Medical, AstraZeneca, Gothenburg
| Published: | September 18, 2024 |
|---|
Outline
Text
Introduction: The international SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with moderate to severe SLE disease in eight countries, of which one was Germany. SPOCS was performed before anifrolumab became available. Type 1 interferon signature status (IFNGS) was analyzed for patients included, in order to analyze possible associations of IFNGS state with disease course and outcomes.
Methods: Patients prospectively followed in SPOCS had moderate to severe SLE active on inclusion (with SLEDAI ≥6 or modified SLEDAI ≥4) and had received standard therapy with ≥6 months of systemic SLE treatment. Data were collected biannually over a period of 36 months. These included type of medication (expressed as percentage of patients receiving antimalarials, corticosteroids, immunosuppressants and biologics), C3 and C4 complement levels and SLEDAI-2K scores, which were also used to quantify the organ systems involved.
Results: In Germany, 74 patients were enrolled (47 with high, 22 with low IFNGS at baseline, no data for 5). Approximately three quarters were treated with antimalarials (72%) and glucocorticoids (72%), two thirds (65%) received methotrexate or immunosuppressants, 22% biologics at baseline. After baseline, disease activity by SLEDAI and complement decrease tended to improve (SLEDAI-2K 10.6±4.7 at baseline (BL), 7.4±7.2 at 3 months (mo), 4.3±4.0 at 36 mo). Oral glucocorticoids tended to decrease over time in IFNGS high patients, but with considerable fluctuation, and remained largely stable in IFNGS low patients (Table 1 [Tab. 1]). Proportions of German patients taking antimalarials and immunosuppressants remained largely stable through 36 months, while the percentages of patients receiving corticosteroids and biologics increased to 79% and 27%, respectively. Of interest, hydroxychloroquine use showed a trend to being lower in IFNGS high patients.
Conclusion: SLE patients with active disease included into the SPOCS study in Germany tended to improve over time with regard to disease activity. IFNGS high patients tended to fluctuate more and had numerically lower hydroxychloroquine use.
